30,227 Shares in IQVIA Holdings Inc. $IQV Acquired by OP Asset Management Ltd

OP Asset Management Ltd purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 30,227 shares of the medical research company’s stock, valued at approximately $5,155,000.

Other institutional investors have also recently made changes to their positions in the company. Strive Asset Management LLC bought a new position in shares of IQVIA during the third quarter valued at about $17,447,000. Picton Mahoney Asset Management grew its stake in shares of IQVIA by 3,086.9% in the third quarter. Picton Mahoney Asset Management now owns 48,824 shares of the medical research company’s stock worth $9,275,000 after purchasing an additional 47,292 shares during the last quarter. WINTON GROUP Ltd purchased a new position in IQVIA during the 3rd quarter valued at about $3,383,000. Artisan Partners Limited Partnership increased its holdings in IQVIA by 4.9% during the 3rd quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock valued at $652,246,000 after purchasing an additional 161,085 shares during the period. Finally, J. Safra Sarasin Holding AG raised its position in IQVIA by 174.3% during the 4th quarter. J. Safra Sarasin Holding AG now owns 12,827 shares of the medical research company’s stock valued at $2,891,000 after purchasing an additional 8,151 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQV stock opened at $191.12 on Friday. The business’s fifty day moving average is $174.43 and its 200 day moving average is $190.07. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock has a market cap of $31.90 billion, a price-to-earnings ratio of 23.68, a PEG ratio of 1.60 and a beta of 1.21. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $247.04.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts expect that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA announced that its board has authorized a stock repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on IQV shares. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a research note on Friday, March 6th. Royal Bank Of Canada began coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective on the stock. HSBC set a $210.00 price objective on shares of IQVIA in a report on Wednesday, June 3rd. Finally, Evercore reaffirmed an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $222.56.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.